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Abstract 70 
 71 
Although the Sensitrite Yeast-One (SYO) and Etest methods are widely utilized, 72 
interpretive criteria are not available for triazole susceptibility testing of Candida or Aspergillus 73 
species. We collected fluconazole, itraconazole, posaconazole and voriconazole SYO and Etest 74 
MICs from 39 laboratories representing all continents for (method-agent-dependent): 11,171 75 
Candida albicans, 215 C. dubliniensis, 4,418 C. glabrata species complex (SC), 157 76 
C. (Meyerozyma) guilliermondii, 676 C. krusei (Pichia kudriavzevii),  298 C. (Clavispora) 77 
lusitaniae, 911 and 3,691 C. parapsilosis sensu stricto (SS) and C. parapsilosis SC, 78 
respectively, 36 C. metapsilosis, 110 C. orthopsilosis, 1,854 C. tropicalis, 244 Saccharomyces 79 
cerevisiae, 1,409 Aspergillus fumigatus, 389 A. flavus, 130 A. nidulans, 233 A. niger, and 302 80 
A. terreus complexes. SYO/Etest MICs for 282 confirmed non-WT isolates were included: 81 
ERG11 (C. albicans), ERG11 and MRR1 (C. parapsilosis), cyp51A (A. fumigatus), and CDR2, 82 
CDR1 overexpression (C. albicans and C. glabrata, respectively). Interlaboratory modal 83 
agreement was superior by SYO for yeast spp., and by the Etest for Aspergillus spp. 84 
Distributions fulfilling CLSI criteria for ECV definition were pooled and we proposed SYO ECVs 85 
for S. cerevisiae, 9 yeast and 3 Aspergillus species, and Etest ECVs for 5 yeast and 4 86 
Aspergillus species. The posaconazole SYO ECV of 0.06 µg/ml for C. albicans and the Etest 87 
itraconazole ECV of 2 µg/ml for A. fumigatus were the best predictors of non-WT isolates. 88 
These findings support the need for method-dependent ECVs, as overall, the SYO appears to 89 
perform better for susceptibility testing of yeast spp. and the Etest for Aspergillus spp. Further 90 
evaluations should be conducted with more Candida mutants. 91 
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Introduction          104 
 105 
The triazoles (fluconazole, isavuconazole, itraconazole, posaconazole, and 106 
voriconazole) are the current treatments for severe candidiasis and aspergillosis (e.g., first-line 107 
or prophylactic, adjunctive, empirical, transition from another agent, salvage therapies) (1-3). 108 
These fungal infections may cause elevated levels of morbidity and mortality among 109 
immunocompromised patients (3-5). The impact of azole resistance and its prevalence has 110 
been widely recognized and various mechanisms of mutational resistance have been elucidated 111 
in the four most common species of Candida, especially in Candida albicans, and in Aspergillus 112 
fumigatus (6-10). In most Candida isolates, azole resistance (or unusually high or increased 113 
MICs) are mostly associated with two main molecular mechanisms among others: an increase 114 
(overexpression) of the azole target azole sterol demethylase or alterations (amino acid 115 
substitutions) in either the gene ERG11 as the enzyme is encoded during the fungal ergosterol 116 
biosynthesis pathway or the MRR1 transcriptional regulator (6,8,9). However, in the case of C. 117 
glabrata, azole resistance has been frequently related to the overexpression or alteration of the 118 
PDR1 gene that regulates efflux pumps (7). On the other hand, the main azole resistance 119 
mechanism in A. fumigatus is due to alterations of the cyp51A gene (10).  120 
 121 
Azole susceptibility testing (yielding minimal inhibitory concentrations [MICs]) is 122 
recommended for all bloodstream and other clinically relevant Candida isolates (1). Although 123 
routine MIC determination for Aspergillus spp. isolates is not usually recommended during initial 124 
aspergillosis therapy, MICs have an important role in identifying potentially resistant isolates, 125 
e.g., isolates from patients failing therapy (2). There are several antifungal susceptibility 126 
methods for the determination of MICs for isolates of both Candida and Aspergillus, including 127 
the broth microdilution M27 and M38 reference methods by the Clinical and Laboratory 128 
Standards Institute (CLSI) (11,12) and the Antifungal Subcommittee of the European Committee 129 
on Antimicrobial Susceptibility Testing (EUCAST) (13) (http://www.eucast.org/ast_of_fungi/). In 130 
addition, the colorimetric broth microdilution Sensititre Yeast-One (SYO; Trek Diagnostic 131 
System, Cleveland, [OH]) as well as the agar diffusion Etest (bioMérieux, Marcy l’Etoile, 132 
France), among other commercial assays, are widely utilized for antifungal susceptibility testing 133 
in the clinical laboratory; these methods are more practical and less time-consuming for routine 134 
use (14-16). 135 
  136 
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The objective of earlier studies evaluating the performance of the SYO and Etest 137 
methods involved the comparison of azole MICs obtained by these methods with those obtained 138 
by the reference assays for prevalent species of Candida and Aspergillus (17-19). Some of 139 
those early studies also evaluated the agreement on the ranking of isolates within existent 140 
categorical endpoints with little attention to the critical issue of interlaboratory reproducibility. 141 
Recently, triazole MIC data for A. fumigatus and C. glabrata mutant strains have been reported 142 
by these commercial methods (20-24). However, lack of suitable clinical data has precluded the 143 
establishment of breakpoints (BPs) for the categorical interpretation of triazole MICs for either 144 
Candida or Aspergillus spp. by these two methods. Therefore, both assays rely on CLSI 145 
available BPs for Candida spp. as interpretive categories as well as for quality control (QC) 146 
(14,16). The proposal of SYO/Etest ECVs (epidemiological cutoff values) for susceptibility 147 
testing of either Candida or Aspergillus isolates with amphotericin B or the echinocandins has 148 
revealed substantial method-dependent differences between some of those values despite the 149 
regulatory requirement to show equivalence to the reference method before marketing (25,26). 150 
Those results emphasize the need to establish method-dependent triazole ECVs for these two 151 
widely used commercial methods for testing the susceptibility of Candida and Aspergillus 152 
isolates to the triazoles in the clinical laboratory. 153 
For the last two years, we have gathered available triazole MICs by both SYO or Etest 154 
assays for isolates of prevalent and non-prevalent yeast species (C. albicans, C. dubliniensis, 155 
C. glabrata species complex, [SC], C. [Meyerozyma] guilliermondii, C. krusei [Pichia 156 
kudriavzevii], C. [Clavispora] lusitaniae, C. parapsilosis SC, including C. parapsilosis sensu 157 
stricto [SS], C. orthopsilosis and C. tropicalis), Saccharomyces cerevisiae and five Aspergillus 158 
species complexes (A. fumigatus [including A. fumigatus SS], A. flavus, A. nidulans, A. niger, 159 
and A. terreus). Additional SYO MIC distributions for less prevalent or common yeast species C. 160 
famata (Debaryomyces hansenii), C. kefyr (Kluyveromyces marxianus), and C. metapsilosis 161 
also were reported when they originated from at least three laboratories and had comparable 162 
modes. From here on we will be using the most “common” clinical names. These triazole MICs 163 
were submitted from 39 independent worldwide laboratories (method/agent/species dependent) 164 
in order: (i) to define MIC distributions by each commercial susceptibility testing method/agent 165 
and species; (ii) to examine the suitability of these distributions for ECV setting, including the 166 
evaluation of interlaboratory modal agreement; and (iii) to define ECVs for each 167 
species/agent/method that fulfilled the CLSI criteria for ECV definition (modal compatibility 168 
among the laboratories, at least 100 MICs for each species/method/agent that originated in >3 169 
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independent laboratories) using the iterative statistical method at the 97.5% cutoff value (27-29) 170 
or the second numerical derivative method when the putative wild-type mode was at the lowest 171 
concentration in the distribution (30).   172 
Although the majority of the isolates evaluated were not assessed for mechanisms of 173 
resistance, we also collected MIC data for 282 known or confirmed mutants (non wild-type [non-174 
WT]) by both methods as follows: SYO and Etest MICs for C. albicans (ERG11), SYO MICs for 175 
C. parapsilosis (ERG11, MRR1) mutants and/or strains with overexpression of the CDR2 gene, 176 
C.  glabrata MICs with overexpression of the CDR1 gene, and SYO and Etest MICs for A. 177 
fumigatus SS harboring cyp51A mutations. These data were submitted mostly from European 178 
laboratories as well as from Argentina, Thailand, South Africa and one published Etest study 179 
(20). SYO data for 58 PDR gene C. glabrata mutants also were submitted, but those data were 180 
not included due to large modal variability of the non-mutants as compared with the global 181 
modes. 182 
 183 
Results and Discussion 184 
 185 
Antimicrobial susceptibility testing for clinical isolates is most useful when either method-186 
and species-dependent BPs or ECVs are available for the isolate and agent evaluated. The BP 187 
categorizes the isolate as either susceptible or resistant and the ECV as either wild-type (WT, 188 
no detectable phenotypic resistance) or non-WT (more likely harboring resistance mechanisms) 189 
(27). Since ECVs are based solely on in vitro data (either MIC or MEC results), classification of 190 
an isolate as a presumptively WT cannot directly predict a successful therapeutic outcome. 191 
Classification of an isolate as a non-WT indicates that it could harbor acquired resistance 192 
mechanisms to the agent being evaluated and would less likely respond to contemporary 193 
therapy (27). However, the putative mechanism of resistance would not necessarily be known in 194 
order to categorize a strain as non-WT. CLSI BPs are based on in vitro and clinical data, genetic 195 
mechanisms of resistance as well as pharmacokinetic/pharmacodynamics parameters (27,28). 196 
EUCAST ECVs and BPs are based on MIC distributions and PK/PD parameters 197 
(http://www.eucast.org/ast_of_fungi/). Therefore, when the BP is available for the isolate and 198 
agent being evaluated that is the value that should be used. To our knowledge, method-199 
dependent SYO or Etest ECVs or BPs for the four triazoles evaluated have not been proposed 200 
for categorization of Candida or Aspergillus isolates. Our ECVs were defined following the 201 
criteria recently published by the CLSI (27). They were based on either SYO or Etest triazole 202 
MIC distributions that originated from 3 to 30 (SYO) or 3 to 11 (Etest) laboratories (species and 203 
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agent dependent) (Tables 1-4) (27). As mentioned before, SYO MICs were submitted from 204 
multiple laboratories for the following mutants:  59 C. albicans ERG11 (4 laboratories) and 39 A. 205 
fumigatus SS cyp51A (5 laboratories), Etest MICs for 81 A. fumigatus cyp51A (7 laboratories 206 
and one published study) (20) (Tables 1, 2 and 5). SYO MICs were received from single 207 
laboratories for the following mutants: 13 C. glabrata and 2 C. albicans with overexpression of 208 
the CDR1 and CDR2 genes, respectively, 78 C. parapsilosis (49 ERG11 and 29 MRR1, 209 
respectively); and Etest MICs for 10 C. albicans (ERG11) (not listed in Tables 1, 2, or 5). The 210 
MICs for these confirmed mutants provided a preliminary assessment of the utility of our 211 
proposed ECVs in recognizing the  non-WT strains. Therefore, since BPs are not available for 212 
these commercial methods, the proposed ECVs in the present study could help the clinician and 213 
laboratory personnel in identifying isolates with possible acquired resistance mechanisms or 214 
could be useful for surveillance or epidemiological studies.   215 
 216 
Although SYO MICs for the species evaluated originated from 30 of the 39 participant 217 
centers, exclusions were made according to the CLSI criteria for ECV definition (Table 1) (27). 218 
During data consolidation, individual SYO MIC distributions of Candida and Aspergillus were not 219 
included in the ECV analysis due to: aberrant or not defined modes, bimodal, or when the 220 
particular mode for a distribution was more than 1 to 2 dilutions from the global mode, or when 221 
there were less than five isolates in the distribution. MIC distributions were also excluded when 222 
the MIC data for the QC isolates were outside the recommended range (14,16). The total of 223 
SYO MICs for the 12 Candida species and the four triazoles pooled for ECV definition from 3 to 224 
30 independent laboratories ranged from 11,171 to 17 isolates, including the data points for C. 225 
parapsilosis SS and C. parapsilosis SC, C. metapsilosis, C. orthopsilosis, C. famata, C. kefyr, 226 
and S. cerevisiae. The SYO MIC distributions for the 59 C. albicans and 39 A. fumigatus SS 227 
mutants from multiple laboratories were also listed in Table 1. In the case of SYO data for 228 
Aspergillus spp., interlaboratory modal consensus was an overall issue given that, of the 229 
submitted data for five species, ECVs were only proposed for voriconazole (4 of 5 species) and 230 
itraconazole (A. niger) (Tables 1 and 3). Of the 903 A. fumigatus listed in Table 1, 71% (640 data 231 
points) were identified as sensu stricto and 29% (263 data points) as species complex 232 
(identification by morphological methods, MALDI-TOF mass spectrometry, or by molecular 233 
methods [e.g., β-tubulin and calmodulin sequencing]) (30). Candida isolates also were identified 234 
to the species level by biochemical tests, MALDI-TOF mass spectrometry and/or molecular 235 
methods in the laboratories submitting the data (31,32); C. parapsilosis and C. glabrata were 236 
submitted mainly as SC (Table 1). 237 
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Table 1 also depicts the SYO modes for Candida and Aspergillus species. The lowest 238 
SYO fluconazole modes (0.25 µg/ml) were for C. albicans, C. dubliniensis and C. kefyr and the 239 
highest mode for C. krusei (64 µg/ml). Similar modal diversity was noted among posaconazole 240 
MICs (modes of 0.01 µg/ml for C. albicans and 1 µg/ml for C. glabrata). However, itraconazole 241 
and voriconazole modes were mostly 0.06 µg/ml to 0.12 µg/ml or 0.008 to 0.03 µg/ml, 242 
respectively. The exceptions were itraconazole modes for C. glabrata (0.5 µg/ml), C. 243 
guilliermondii and C. krusei (0.25 µg/ml) and voriconazole modes for C. guilliermondii, C. 244 
tropicalis (0.06 µg/ml), C.  glabrata and C. krusei (0.25 µg/ml). Most SYO modes for the C. 245 
parapsilosis complex were +/-1 double dilution, but all posaconazole modes for the four species 246 
in the complex were 0.03 µg/ml. SYO voriconazole modes for Aspergillus spp. and the 247 
itraconazole mode for A. niger ranged from 0.12 to 0.5 µg/ml. As expected, SYO modes for the 248 
C. albicans and A. fumigatus mutants were much higher than those for the non-mutant isolates 249 
and we observed an overlap between both groups of MICs among the lower drug 250 
concentrations (Table 1). Therefore, the SYO data for Candida spp. showed excellent modal 251 
agreement, while most SYO data points for Aspergillus spp. were unsuitable for the ECV 252 
definition pool as previously reported among SYO posaconazole data for A. fumigatus (23). 253 
 254 
Eleven of the 39 laboratories contributed Etest MICs for the four more prevalent Candida 255 
spp., C. krusei, and Aspergillus spp. Eight laboratories, including a published study (20), 256 
contributed Etest voriconazole and itraconazole data for the 75 and 81 A. fumigatus SS 257 
mutants, respectively (Tables 2 and 5). A total of 64% (712 of the 1,112 itraconazole MICs) of A. 258 
fumigatus isolates and most Candida isolates were identified at the species level (31,32), but C. 259 
glabrata and C. parapsilosis mainly as species complex. Therefore, we were unable to provide 260 
the potential antifungal susceptibility differences among the species in the C. parapsilosis SC, 261 
as we did by the SYO method (Table 1). Modal variability among the Etest MIC distributions 262 
entering the ECV definition data pool also precluded our ECV definition for C. albicans and 263 
fluconazole; C. glabrata and both itraconazole and posaconazole; C. parapsilosis and 264 
itraconazole and C. krusei and fluconazole. However, most Etest data points for the 265 
Aspergillus/agent combinations were suitable for the ECV definition pool; although we observed 266 
modal discrepancies for itraconazole and voriconazole versus A. terreus. Consequently, we 267 
collected more suitable Etest data for Aspergillus spp. while the overall SYO data for Candida 268 
spp. was superior. The lowest Etest modes were for C. parapsilosis versus fluconazole and 269 
posaconazole (0.5 and 0.01 µg/ml, respectively), C. tropicalis versus itraconazole (0.03 µg/ml), 270 
and C. albicans versus voriconazole (0.008 µg/ml). All Etest modal values for Aspergillus spp. 271 
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ranged between 0.12 and 0.25 µg/ml, except for the itraconazole modes for A. fumigatus (0.5 272 
µg/ml), and for A. niger (1 µg/ml). Etest modes for the A. fumigatus mutants also were much 273 
higher than those for the non-mutant isolates.  274 
 275 
Tables 3 and 4 depict the proposed ECOFFinder SYO and Etest triazole ECVs, 276 
respectively, for 97.5% of the modelled MIC population for the species and triazole 277 
combinations that fulfilled the CLSI criteria for ECV calculation (27). There was no need to 278 
weigh the data since none of the individual distributions contributed >50% of the total. In 279 
addition to SYO ECVs for the prevalent Candida spp., fluconazole ECVs were proposed for C. 280 
orthopsilosis (4 µg/ml) and S. cerevisiae (16 µg/ml) (Table 3). Although fluconazole ECVs for C. 281 
parapsilosis SS and SC were the same (2 µg/ml), the other ECVs for C. parapsilosis SS were 282 
one dilution higher. To our knowledge, ECVs for C. parapsilosis SS or any other member of this 283 
complex and for S. cerevisiae are not yet available for the reference methods (26,28) 284 
(http://www.eucast.org/ast_of_fungi/). Due to aberrant modes by the Etest, we only defined 285 
voriconazole Etest ECVs of 0.03 to 2 µg/ml for five Candida spp. and ECVs of 0.12 to 64 µg/ml 286 
for the other three agents and 3 to 4 species (Table 4). However, we proposed ECVs for three to 287 
four relevant Aspergillus spp. (2,4,5). Inconsistent itraconazole and voriconazole modes for A. 288 
terreus from four laboratories as well as insufficient posaconazole and voriconazole MICs for A. 289 
nidulans (data submitted from only two laboratories) precluded ECV definition for these two 290 
species/agents (27) (data not shown in Table 2). In Table 6, we compared our SYO and Etest 291 
ECVs with the approved CLSI ECVs as listed in the new edition of the M59 document (26). In 292 
general, SYO ECVs were one to two dilutions higher than those for the CLSI or Etest methods. 293 
In some instances, such as for fluconazole and voriconazole versus C. glabrata, among others, 294 
SYO and CLSI ECVs of 64 and 8 µg/ml and 2 and 0.25 µg/ml, respectively, have been defined 295 
(26). All these observations underscore the need for method-dependent ECVs in order to 296 
properly categorize the MIC for the infecting isolate being evaluated as either WT or non-WT. It 297 
also demonstrates that while commercial systems can successfully establish ‘equivalence’ 298 
according to FDA criteria, the pooling of data from multiple laboratories can more easily detect 299 
differences between these assays and the reference method, at least in what is measured as 300 
the wild type. 301 
 302 
As mentioned above, the main role of the ECV is to identify the strains that could harbor 303 
intrinsic or acquired resistance mechanisms (non-WT or mutant isolates) (27,28). CLSI MICs for 304 
Candida and Aspergillus mutants are readily available in the literature (6-10,33-36), but they are 305 
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scarce by the commercial methods (20-24). A total of 162 SYO and Etest MICs for C. albicans, 306 
C. glabrata and C. parapsilosis mutants were received. The number of SYO MICs above the 307 
ECVs of the four triazoles for the 59 ERG11 C. albicans mutants was agent-dependent. The 308 
posaconazole ECV of 0.06 µg/ml recognized the highest percentage of mutants (55/59: 93%), 309 
followed by the itraconazole ECV of 0.12 µg/ml (53/59: 90%), the voriconazole ECV of 0.01 310 
µg/ml (52/59: 88%) and the fluconazole SYO ECV of 1 µg/ml (48/59 (81%). These C. albicans 311 
mutants had the following ERG11 substitutions: F145L, Y132H, S442F, S405F, G464S, A114S, 312 
G464S, F145T, T22OL, and P98A (alone or in combination). Although high CLSI triazole MICs 313 
have been documented for most of those substitutions (6,8,33-35), T22OL and P98A (alone or 314 
in different combinations with E266D, G448R, V437I, V488I, K143R, and Y132H/X) have not 315 
been previously reported. Considering their high MICs of >8 µg/ml (Table 1), it seems that these 316 
strains also could harbor combined resistance mechanisms (e.g., the most common efflux pump 317 
overexpression +erg11 overexpression and/or mutation). These molecular combinations are due 318 
to aneuploidy (duplication of the chromosome 5 or multiplication of its long arm). However, we 319 
did not receive efflux pump overexpression data for the 59 C. albicans mutants. On the other 320 
hand, in Table 5 we listed the C. albicans and A. fumigatus mutants that according to our 321 
method-dependent ECVs could be categorized as either WT (MICs =< each ECV) and/or non-322 
WT (MICs >the ECV). Those substitutions have been reported as both “susceptible and 323 
resistant” isolates using CLSI methodologies and BPs (8,33-35). Regarding data from the single 324 
laboratories, SYO MICs of the four agents for the two C. albicans and 11 of the 13 C. glabrata 325 
strains from single laboratories with overexpression of the CDR2 and CDR1 gene efflux pumps, 326 
respectively, were above the four ECVs (data not shown in Table 5). However, only the 327 
fluconazole and voriconazole ECVs (2 and 0.03 µg/ml, respectively) recognized >96% of the 78 328 
C. parapsilosis mutants. Therefore, the potential ability of our SYO ECVs in recognizing >90% of 329 
the isolates with mechanisms of resistance among the most prevalent Candida spp. (C. 330 
albicans, C. glabrata) provided a preliminary indication of their clinical value. More data points 331 
for other Candida spp. mutants would better assess the utility of the SYO method for yeast 332 
testing in the clinical laboratory.  333 
 334 
In the present study, a total of 75 to 81 Etest (voriconazole and itraconazole, 335 
respectively) and 39 SYO (voriconazole) MICs for A. fumigatus SS cyp51A mutants, were 336 
evaluated. Our proposed Etest itraconazole ECV of 2 µg/ml for A. fumigatus had a superior 337 
performance in recognizing the cyp51A mutants (78/81: 96%) than the voriconazole Etest ECV 338 
of 0.5 µg/ml (50/75: 67%) and the SYO ECV of 1 µg/ml (26/39: 67%) (Table 5). Etest 339 
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itraconazole MICs were above the ECV for the following mutations: 48 TR34/L98 (59%), 12 G54 340 
(15%), 9 M220 (11%), 5 G448S (6%) and 7 (9%) miscellaneous mutations, including two 341 
TR46/Y121F (Data not listed in Table 5). However, cyp51A G54 changes have been linked in 342 
the literature with cross-resistance to both itraconazole and posaconazole and M220 with either 343 
high or low triazole MICs (36). An overlap between posaconazole MICs for non-mutants and a 344 
much larger number of mutants of A. fumigatus by three antifungal susceptibility methods (CLSI, 345 
EUCAST and Etest) also has been reported (23). These preliminary results for Aspergillus spp. 346 
indicated that the Etest appears to be a superior method for detecting mutations in A. fumigatus 347 
as well as for testing other Aspergillus spp. Once again, these results underscore the need for 348 
method-dependent ECVs. As far as the SYO data for Aspergillus spp., further collaborative 349 
studies should evaluate the endpoint determination; both color change and growth inhibition 350 
have been have reported in the literature.   351 
 352 
In conclusion, we proposed method-dependent SYO and Etest ECVs for various 353 
species/triazole combinations for which suitable data were available from multiple laboratories 354 
(3 to 30). Substantial data with excellent interlaboratory modal agreement were evaluated by the 355 
SYO method for Candida and other yeasts species, including MIC distributions for the C. 356 
parapsilosis complex (C. parapsilosis SS, C. metapsilosis and C. orthopsilosis) and S. 357 
cerevisiae. Because of that, we proposed SYO ECVs for 8 to 10 yeast species and the four 358 
triazoles evaluated, as well as for C. orthopsilosis and S. cerevisiae versus fluconazole. We also 359 
provided MIC ranges, and more importantly, modes for other less prevalent yeast species. On 360 
the other hand, interlaboratory modal agreement was better by the Etest for Aspergillus than for 361 
yeast  species. As a result, we proposed Etest ECVs of itraconazole, posaconazole and 362 
voriconazole for three to four Aspergillus spp. and voriconazole ECVs for the four most 363 
prevalent Candida spp.  and C. krusei. Finally, the SYO posaconazole ECV of 0.06 µg/ml for C. 364 
albicans and the Etest itraconazole ECV of 2 µg/ml for A. fumigatus were the best predictors in 365 
recognizing the non-WT or mutants (highest percentage of MICs for mutants that were above 366 
the ECV). Although ECVs of fluconazole and voriconazole for C. parapsilosis recognized >96% 367 
of the non-WT isolates, results were unsatisfactory with posaconazole and itraconazole ECVs. 368 
Data for mutants for other Candida spp. would better assess the method-dependent proposed 369 
ECVs. The SYO method appears to yield more suitable MIC data for testing most Candida spp. 370 
and the Etest for Aspergillus spp.  371 
 372 
Materials and Methods 373 
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 374 
Isolates: The Candida and other yeast isolates evaluated were recovered mostly from 375 
blood and other normally sterile sites from patients with candidemia or other deep infections 376 
(>90%) as well as superficial, oral, vaginal and thrush. The Aspergillus isolates also were 377 
recovered  from deep infections, sterile and other sites (mostly [>90%] bronchoalveolar lavage 378 
fluids, sputum) at the following medical centers: VCU Medical Center, Richmond, VA, USA; 379 
Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, 380 
Majadahonda, Madrid, Spain; Unité de Parasitologie, Mycologie, Département de Bactériologie 381 
Virologie Hygiène Mycologie Parasitologie, Créteil, France; Grupo de Infección Grave, Instituto 382 
de Investigación Sanitaria La Fe, Valencia, Spain; Unidad de Gestión Clínica de Enfermedades 383 
Infecciosas y Microbiología, Hospital de Valme, Seville, Spain; Department of Internal Medicine, 384 
National Taiwan University Hospital and College of Medicine, Taipei, Taiwan; Public Health 385 
Ontario, Toronto, Ontario, Canada; Klinisk Mikrobiologi, Karolinska, Universitetlaboratoriet,  386 
Karolinska, Universitetssjukhuset, Stockholm, Sweden; Université Paris-Descartes, Faculté de 387 
Médecine, APHP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, 388 
Service de Microbiologie, Paris, France; Laboratorio de Micología y Diagnóstico Molecular, 389 
Cátedra de Parasitología y Micología, Facultad de Bioquímica y Ciencias Biológicas, 390 
Universidad Nacional del Litoral, Consejo Nacional de Investigaciones Científicas y 391 
Tecnológicas (CONICET), Santa Fe, Argentina; Universidad Autónoma de Nuevo León, Mexico; 392 
National Institute for Communicable Diseases (Centre for Healthcare-Associated Infections, 393 
Antimicrobial Resistance and Mycoses), a Division of the National Health Laboratory Service 394 
and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 395 
Hospital General Universitario Gregorio Marañón, Madrid, Spain; SA Pathology, National 396 
Mycology Reference Centre, Adelaide, S. Australia; Division of Hygiene and Medical 397 
Microbiology, Medical University of Innsbruck, Innsbruck, Austria; Departamento de 398 
Microbiología, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain; 399 
Servicio de Microbilogía, Hospital Universitario Cruces, Barakaldo, Spain; Servicio de 400 
Microbiología, Hospital Universitario Central de Asturias, Asturias, Spain; Departamento de 401 
Inmunología, Microbiología y Parasitología, Facultad de Medicina y Enfermería, Universidad del 402 
País Vasco/Euskal Herriko Unibertsitatea, UPV/EHU, Bilbao, Spain; Departamento de 403 
Biomedicina, Biotecnología y Salud Pública, Universidad de Cádiz, Cadiz, Spain; Hospital de 404 
Alcañiz, Alcañiz (Teruel), Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 405 
Institute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy; University of 406 
Pittsburgh, Pittsburgh, Pennsylvania, USA; Department of Pharmaceutical Technology and 407 
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Biochemistry, Faculty of Chemistry, Gdańsk University of Technology, Gdańsk, Poland; 408 
Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, University of 409 
Technology, Gdansk, Poland; Department of Biomedical Sciences for Health, Università degli 410 
Studi di Milano, Milan, Italy; Mayo Clinic, Rochester, MN, USA; Microbiology Laboratory, 411 
Ospedale San Gerardo, Monza, Italy; Microbiology and Virology Unit IRCCS Policlinico San 412 
Matteo, Pavia, Italy; Microbiology Section, Humanitas Research Hospital, Milan, Italy; 413 
Microbiology Laboratory, A.O. Spedali Civili, Brescia, Italy; Microbiology Laboratory, Fondazione 414 
IRCCS Cà Granda O. Maggiore Policlinico, Milan, Italy; Microbiology Laboratory, Niguarda 415 
Hospital, Milan, Italy; Clinical Microbiology Laboratory, Attikon Hospital, Medical School, 416 
National and Kapodistrian, University of Athens, Athens, Greece; Laboratório Especial de 417 
Micologia, Disciplina de Infectologia, Escola Paulista de Medicina, Universidade Federal de São 418 
Paulo, São Paulo, SP, Brazil; Microbiology Institute, ASST ‘Papa Giovanni XXIII, Bergamo, Italy; 419 
Unidad de Micología, Servicio de Microbiología, Hospital Universitario La Fe, Valencia, Spain; 420 
Microbiology-ASST Lariana, Como, Italy; and Medicina di Laboratorio, IRCCS Policlinico San 421 
Donato, Milan, Italy. 422 
 423 
The total of submitted triazole MICs of the four triazoles by both SYO and/or Etest 424 
methods from 3 to 30 laboratories for yeast species were as follows (method-agent dependent) 425 
(Tables 1 and 2): 11,171 C. albicans, 215 C. dubliniensis, 4,418 C. glabrata SC (including 349 426 
C. glabrata SS), 157 C. guilliermondii, 676 C. krusei, 298 C. lusitaniae, 3,691 C. parapsilosis 427 
SC, 922 C. parapsilosis SS, and 1,854 C. tropicalis isolates were evaluated for ECV definition 428 
(Tables 1 and 2). SYO MICs for other less common Candida and yeast species from at least 429 
three laboratories were collected for 25 C. famata, 55 C. kefyr, 36 C. metapsilosis, and 110 C. 430 
orthopsilosis as well as SYO data for 244 isolates of S. cerevisiae. In addition, we pooled SYO 431 
and mostly Etest data for the four most prevalent Aspergillus complexes as follows (method-432 
agent dependent): 1,409 A. fumigatus, 389 A. flavus, 103 A. nidulans, 233 A. niger, and 302 A. 433 
terreus isolates originating from 3 to 11 independent laboratories. 434 
 435 
We also received a total of 282 MICs for mutants:  59 SYO and 10 Etest MICs, 436 
respectively, for C. albicans (Erg11 gene mutations), 2 C. albicans and 13 C. glabrata, 437 
respectively, (overexpression of CDR2 or CDR1 efflux pumps, respectively), and 78 C. 438 
parapsilosis (Erg11 and MRR1). SYO and Etest MICs were gathered for 39 and 81 strains for A. 439 
fumigatus SS mutant isolates, respectively, with cyp51A gene mechanisms of resistance 440 
(TR34/L98H, G54, M220, and others) from five to seven participant laboratories and one 441 
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previous Etest study (20) (Tables 1-2 and Table 5). The isolates were identified at each medical 442 
center by conventional and molecular methodologies that included macro-and microscopic 443 
morphology, thermotolerance (incubation at 50°C), MALDI-TOF and β-tubulin and calmodulin 444 
sequencing (31,32). Since molecular identification was not performed for all the isolates 445 
evaluated in the present study, we listed the non-mutant isolates in the respective Tables as the 446 
complexes of C. glabrata or C. parapsilosis or Aspergillus spp. Strains of A. fumigatus, C. 447 
albicans and C. glabrata that were submitted as having mutations were screened in the 448 
participant laboratories using published protocols. (31,36-38). 449 
 450 
At least one of following quality control (QC) isolates: C. parapsilosis ATCC 22019, C. 451 
krusei ATCC 6258 and Paecilomyces variottii ATCC MYA-3630 and/or reference isolates A. 452 
fumigatus ATCC MYA-3626 and A. flavus ATCC MYA-204304 were evaluated by the two 453 
methods in each of the participant laboratories (14,16). MIC data were not included in the study 454 
unless the participant laboratories reported that their MICs for the individual QC isolates used in 455 
each center were within the expected MIC ranges. 456 
 457 
Antifungal susceptibility testing. Triazole SYO and Etest MICs were obtained by the 458 
two commercial antifungal susceptibility methods by following the manufacturer’s guidelines (14-459 
16). The SYO MIC was the first blue or purple well after 24 h (Candida) or mostly 48 h 460 
(Aspergillus) of incubation and isolates, respectively). The Etest MIC was the lowest drug 461 
concentration at which the border of the growth-free elliptical inhibition intercepted the scale on 462 
the antifungal strip, after 24 to 48 h, as needed; trailing growth was allowed solely for the 463 
definition of Etest MICs for Candida isolates. 464 
 465 
Definitions. The definition of the ECV as a categorical endpoint has been widely 466 
described as well as above (27,28). Briefly, the ECV is the highest MIC/MEC distribution of the 467 
WT population and is established by using reliable MIC/MEC distributions from at least three 468 
laboratories. A non-WT organism usually shows reduced susceptibility to the agent being 469 
evaluated compared to the WT (no phenotypic resistance) population. In addition to MIC 470 
distributions, the ECV calculation takes into account each laboratory distribution mode, the 471 
inherent variability of the test (usually within one doubling dilution), and that the ECV should 472 
encompass 95 to 97% of isolates. We used those same criteria and requirements for 473 
establishing our proposed Etest and SYO method-dependent ECVs. Most published ECVs are 474 
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based on reference MIC distributions, and ECVs based on other methods could be different, as 475 
it has been shown in our study (Table 6).  476 
 477 
Data collation and analyses. Triazole MICs were submitted from 39 independent 478 
worldwide laboratories (method/agent/species dependent) in order: (i) to define MIC 479 
distributions by each commercial susceptibility testing method/agent and species; (ii) to examine 480 
the suitability of these distributions for pooling prior to ECV setting, including the evaluation of 481 
interlaboratory modal agreement; and (iii) to estimate ECVs for each species/agent/method that 482 
fulfilled the CLSI criteria for ECV definition after pooling (at least 100 MICs for each 483 
species/method/agent that originated in >3 independent laboratories) (27,28). ECVs were 484 
estimated by the iterative statistical method at the 97.5% cutoff value (29) or the second 485 
numerical derivative method when the putative wild-type mode was at the lowest concentration 486 
in the distribution (30) (Tables 2 and 4). SYO MIC distributions for less common yeast species 487 
(C. famata and C. kefyr) and C. metapsilosis also were reported when they originated from at 488 
least three laboratories and had comparable modes. 489 
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Table 1. SYO pooled triazole MIC distributions for species of Candida, Saccharomyces and Aspergillusa 
 
Agent and species 
 
 
 
No. 
isolates 
 
No. labs 
used/ 
Totalb 
 
Number of isolates with MIC (µg/ml) of:c 
 
 
Fluconazole 
   
0.06 
 
0.12 
 
0.25 
 
0.5 
 
1 
 
2 
 
4 
 
8 
 
16 
 
32 
 
64 
 
>128 
 
C. albicans 
 Confirmed ERG11 
mutants 
 
11,171  
59 
28/30 
4/4 
12 1,016 
3 
4,252 
1 
4,152 
4 
978 
3 
238 122 
1 
82 
2 
78 
2 
33 49 
43 
159  
C. dubliniensis 195 7/10  48 64 57 13 6 3 2  1 1   
C. famata 23 3/6   1 2 11 5 3 1      
C. glabrata  4,418 30/30  13 9 23 64 152 375 1,049 1,330 691 216 496  
C. guilliermondii 153 8/13  2 1 6 20 36 46 19 10 6 4 3  
C. kefyr 55 3/4  13 25 15 2         
C. krusei 537 15/16  1 1 1   3 8 43 193 220 67  
C. lusitaniae 298 12/12  16 41 75 99 43 12 5 1 4 1 1  
C. parapsilosis  
C. parapsilosis SS 
C. metapsilosis 
C. orthopsilosis 
3,691 
911 
36 
110 
 
28/30 
5/5 
4/4 
5/5 
 89 
18 
 
3 
502 
118 
1 
4 
1,210 
282 
2 
29 
958 
216 
17 
43 
421 
121 
10 
15 
221 
74 
5 
8 
151 
53 
 
4 
82 
19 
1 
2 
27 
6 
 
 
19 
4 
 
1 
11 
 
 
1 
 
C. tropicalis 1,854 24/28  20 82 270 701 482 129 53 19 24 14 60  
S. cerevisiae 
 
244 3/3  4 3 9 40 70 76 26 10 4 2   
Itraconazole   0.008 0.01 0.03 0.06 0.12 0.25 0.5 1 2 4 8 >16  
C. albicans 
 Confirmed ERG11 
mutants 
 
7,843 
59 
27/30 
4/4 
69 995 2,696 
2 
2,754 
2 
905 
2 
164 
5 
77 
11 
27 
    3 
14 
7 
 
7 
4 
9 
 
126 
23 
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C. dubliniensis 125 6/8  13 21 47 27 7 2 5 1   2  
Itraconazole (Cont.)   0.008 0.01 0.03 0.06 0.12 0.25 0.5 1 2 4 8 >16  
C. famata 18 3/5  1 1 2 3 7 3 1      
C. glabrata  3,594 29/30  12 19 42 112 428 1,335 910 195 71 26 444  
C. guilliermondii 149 9/13  3  8 31 55 37 10 2   3  
C. kefyr 45 3/3  5 10 17 12 1        
C. krusei 574 13/16  4 3 14 69 283 156 33 2 1  9  
C. lusitaniae 171 8/11  11 12 52 60 28 7 1      
C. parapsilosis 
C. parapsilosis SS 
C. metapsilosis 
C. orthopsilosis 
3,353 
730 
32 
88 
 
23/30 
4/5 
4/4 
3/4 
 
 
 
 
209 
68 
3 
2 
 
570 
79 
3 
13 
1,098 
237 
12 
35 
1,150 
254 
11 
26 
252 
83 
1 
12 
59 
6 
2 
 
13 
3 
1 1    
C. tropicalis 1,399 23/29  14 51 138 513 508 126 16 4 1 5 23  
S. cerevisiae 41 3/3  1 1 3 21 11 2 2      
A. niger 233 6/7  18 23 48 69 44 17 6   1 7  
Posaconazole   0.008 0.01 0.03 0.06 0.12 0.25 0.5 1 2 4 8 >16  
C. albicans 
Confirmed ERG11 
mutants 
6,729 
59 
27/30 596 
1 
2,768 2,318 
3 
587 
1 
175 
4 
96 
9 
56 
8 
32 
7 
10 
1 
3 
1 
60 28 
24 
 
C. dubliniensis 185 7/8 35 56 63 25 4   2      
C. glabrata  2,999 25/29 4 5 28 39 50 153 590 1,145 579 62 251 93  
C. guilliermondii 111 9/12 3 1 9 15 27 35 18 3      
C. kefyr 40 3/3   7 13 13 5 2       
C. krusei 562 13/15 1 1 3 20 90 264 151 25 5  2   
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C. lusitaniae 172 11/11 17 49 58 36 10  1 1      
Posaconazole (Cont.)   0.008 0.01 0.03 0.06 0.12 0.25 0.5 1 2 4 8 >16  
C. parapsilosis  
C. parapsilosis SS 
C. metapsilosis 
C. orthopsilosis 
3,085 
670 
17 
30 
26/30 
5/5 
3/4 
3/4 
 
136 
40 
 
 
538 
127 
3 
5 
1,091 
206 
7 
14 
915 
193 
4 
7 
297 
69 
3 
4 
86 
31 
 
11 
2 
 
7 1 1  
2 
2  
C. tropicalis 1,366 23/29 16 50 107 250 408 336 147 22 6  17 7  
S. cerevisiae 41 3/3    3 6 20 9 2 1     
Voriconazole   0.008 0.01 0.03 0.06 0.12 0.25 0.5 1 2 4 8 >16  
C. albicans 
Confirmed ERG11 
mutants 
8,747 
59 
29/30 
4/4 
5,947 
3 
1,691 
4 
481 
4 
222 
1 
111 
4 
82 
1 
47 
7 
22 
6 
10 
3 
15 
5 
76 
2 
43 
19 
 
C. dubliniensis 215 7/9 182 21 5 3 1 2   1     
C. famata 25 3/5 5 10 4 2 2 2        
C. glabrata  3,255 24/30 23 29 65 189 486 911 824 340 136 156 82 14  
C. guilliermondii 157 11/12 8 10 32 46 34 10 11 4 1   1  
C. kefyr 55 3/3 46 8 1           
C. krusei 676 14/16 2 1 1 16 108 291 199 42 11 3 1 1  
C. lusitaniae 248 11/12 120 70 32 15 4 1 2 4      
C. parapsilosis  
C. parapsilosis SS 
C. metapsilosis 
C. orthopsilosis 
 2,670 
718 
30 
20 
26/30 
5/5 
3/4 
3/4 
1,213 
261 
2 
1 
695 
185 
10 
8 
364 
122 
11 
3 
210 
80 
4 
6 
103 
47 
2 
2 
50 
12 
1 
 
16 
5 
10 
4 
9 
2 
    
C. tropicalis 1,637 19/28 45 92 227 466 443 200 70 25 20 9 23 17  
S. cerevisiae 41 3/3 1 3 17 15 2 2 1       
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aIncluding the complexes of C. glabrata, C. parapsilosis and Aspergillus spp.; the cyp51A mutants are A. fumigatus SS; C. famata (D. hansenii), C. guilliermondii 
(M. guilliermondii), C. kefyr (K. marxianus), C. krusei (P. kudriavzevii) and C. lusitaniae (Clavispora lusitaniae). 
 
bTotal number of laboratories included in the ECV definition pool/total number of laboratories that submitted data.  
cData are from between 3 and 30 laboratories determined by the colorimetric broth microdilution SYO method (14); the highest number in each row (showing the 
most frequent MIC or the mode) is in bold. 
 
A. fumigatus 
Confirmed Cyp51A 
mutants 
903 
39 
 
8/8 
5/5 
2 7 35 64 157 
3 
396 
4 
179 
8 
33 
3 
8 
4 
7 
5 
7 
2 
8 
10 
 
 
Voriconazole (Cont.)    0.008 0.01 0.03 0.06 0.12 0.25 0.5 1 2 4 8 >16  
A. flavus 389 6/7 5 1 14 32 89 139 59 29 16 1 0 4  
A. niger 74 3/6    1 9 19 33 12      
A. terreus 302 5/6 6 5 16 19 48 122 69 15 2     
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Table 2. Etest Triazole pooled MIC distributions for species of Candida and Aspergillusa 
 
Agent and species 
 
 
 
No. 
isolates 
 
No. labs 
used/ 
totalb 
 
Number of isolates with MIC (µg/ml) of:c 
 
Fluconazole 
   
0.03 
 
0.06 
 
0.12 
 
0.25 
 
0.5 
 
1 
 
2 
 
4 
 
8 
 
16 
 
32 
 
64 
 
>128 
C. glabrata  356 7/10      1 4 13 34 50 79 88 36 13 28 10 
C. parapsilosis  639 9/9 3 19 68 131 153 138 66 21 9 7 20  4 
C. tropicalis 368 9/10 3 5 11 61 96 120 47 11 4 1 4 4 1 
 
Itraconazole 
   
<0.004 
 
0.008 
 
0.01 
 
0.03 
 
0.06 
 
0.12 
 
0.25 
 
0.5 
 
1 
 
2 
 
4 
 
8 
 
>16 
C. albicans 975 
 
8/9 
 
7 
 
55 145 237 
 
295 150 27 
 
19 
 
16 
 
6 
 
7 
 
5 6 
C. krusei 101 3/3    1  2 9 36 35 7 7 1 3 
C. tropicalis 165 5/8 2 12 23 39 30 22 15 11 7 2 1 1  
A. fumigatus  
Confirmed Cyp 51A 
mutants  
1,112 
81 
10/10 
8/8 
 4 1 3 30 
1 
 
56 157 483 
1 
268 73 
1 
12 
7 
5 
4 
20 
67 
A. flavus  250 7/8   1 4 19 37 103 69 16 1    
A. nidulans  130 4/4   1 1 13 39 34 23 11 7  1  
A. niger  176  4/5     1 1 2 5 25 71 45 17 5 4 
 
Posaconazole 
   
<0.004 
 
0.008 
 
0.01 
 
0.03 
 
0.06 
 
0.12 
 
0.25 
 
0.5 
 
1 
 
2 
 
4 
 
8 
 
>16 
C. albicans 305 
 
4/6 
 
6 
 
29 94 
 
102 44 17 
 
9 
 
3 
 
1 
 
 
 
   
C. krusei 48 3/3     1 5 17 16 7     2 
C. parapsilosis  162 4/5 8 26 51 37 23 9 3 2   1  2 
C. tropicalis 101 4/5  9 21 32 21 4 8 3 1  1 1  
A. flavus  204 7/7   1 4 14 70 96 17 2     
A. niger  168 4/5    5 16 58 73 15 1     
A. terreus  194 5/5    8 47 105 27 4 2  1   
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aIncluding the complexes of C. parapsilosis, C. glabrata and Aspergillus species; the Cyp 51A mutants are A. fumigatus SS; C. krusei (P. kudriazveii).  
bTotal number of laboratories included in the ECV definition pool/total number of study laboratories and one published study (20) that submitted data.  
cData are from between 3 and 11 laboratories and were determined by the agar diffusion Etest method (15); the highest number in each row (showing the most frequent MIC or the 
mode) is in bold. 
 
 
 
Voriconazole  
(Cont. Table 2) 
 
<0.004 
 
0.008 
 
0.01 
 
0.03 
 
0.06 
 
0.12 
 
0.25 
 
0.5 
 
1 
 
2 
 
4 
 
8 
 
>16 
C. albicans 2,159 
 
8/11 
 
485 803 491 
 
158 104 42 22 
 
20 
 
11 
 
5 
 
7 
 
1 10 
C. glabrata  551 8/9  7 11 20 37 105 143 96 63 30 15 14 10 
C. krusei 130 6/6   1 2 3 20 30 45 24 5  2  
C. parapsilosis   506 7/9 4 20 46 97 167 100 39 15 4 4 8 1 1 
C. tropicalis 260 6/10 4 4 12 28 82 88 22 14 5   1  
A. fumigatus  
Confirmed Cyp 51A 
mutants 
1,409 
75 
11/11 
8/8 
1 6 2 30 132 
5 
633 
6 
473 
7 
100 
8 
19 
13 
7 
15 
3 
3 
2 
1 
1 
17 
A. flavus  257 7/7   1  18 84 103 39 10 1   1 
A. niger  173 4/5   2 3 22 37 81 25 1 1   1 
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Table 3. Method-dependent SYO ECOFFinder ECVs of four triazoles for species of Candida, 
Saccharomyces, and Aspergillusa 
 
Agent and species 
 
No. 
isolates 
 
No. labs 
used/total 
 
MIC (µg/ml) 
 
ECVs (µg/ml)b 
 
 
Range Mode  
 
Fluconazole       
C. albicans 11,171 28/30 0.06->128 0.25 1  
C. dubliniensis 195 7/10 0.12-64 0.25 1 
 
C. glabrata 4,418 30/30 0.12->128 16 64 
 
C. guilliermondii 153 8/13 0.12->128 4 16  
C. krusei 537 15/16 0.12->128 64 128  
C. lusitaniae 298 12/12 0.12->128 1 4 
 
C. parapsilosis  
C. parapsilosis SS 
C. orthopsilosis 
3,691 
911 
110 
28/30 
5/5 
5/5 
0.12->128 
0.12-64 
0.12-≥128 
0.5 
0.5 
1 
2 
2 
4 
 
C. tropicalis 1,854 24/28 0.12->128 1 4 
 
S. cerevisiae 244 3/3 0.12-64 4 16 
 
 
Itraconazole 
      
C. albicans 
 
7,843 27/30 
 
0.008->16 
 
0.06 
 
0.12 
 
 
C. dubliniensis 125 6/8 0.01->16 0.06 0.25 
 
C. glabrata  3,594 29/30 0.01->16 0.5 2 
 
C. guilliermondii 149 9/13 0.01->16 0.25 1 
 
C. krusei 574 13/16 0.01->16 0.25 1 
 
C. lusitaniae 171 8/11 0.01-1 0.12 0.5 
 
C. parapsilosis  
C. parapsilosis SS  
3,353 
730 
23/30 
4/5 
0.01-4 
0.01-1 
0.12 
0.12 
0.25 
0.5 
 
C. tropicalis 1,399 23/29 0.01->16 0.12 0.5 
 
A. niger  233 6/7 0.01-≥16 0.12 1 
 
 
Posaconazole 
    
 
 
C. albicans 
 
6,729 
 
27/30 
 
0.008->16 
 
0.01 
 
0.06 
 
 
C. dubliniensis 185 7/8 0.008-1 0.03 0.12  
C. glabrata  2,999 25/29 0.008->16 1 4  
C. guilliermondii 111 9/12 0.008-1 0.25 1  
C. krusei 562 13/15 0.008-8 0.25 1  
C. lusitaniae 172 11/11 0.008-1 0.03 0.12  
C. parapsilosis   
C. parapsilosis SS 
3,085 
670 
26/30 
5/5 
0.008->16 
0.008-8 
0.03 
0.03 
0.12 
0.25 
 
C. tropicalis 1,366 23/29 0.008->16 0.12 1  
       
 
Voriconazole  
(Cont. Table 3) 
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aIncluding the complexes of C. parapsilosis, C. glabrata and Aspergillus species; C. guilliermondii (M. 
guilliermondii), C. krusei (P. kudriavzevii) and C. lusitaniae (Clavispora lusitaniae. Modal variability or 
insufficient data precluded the proposal of ECVs for some species of both Candida and Aspergillus. 
bECOFFinder ECVs for 97.5% of the statistically modelled population based on MICs by the colorimetric 
broth microdilution SYO method (14,29) except where indicated by superscript c, referring to footnote c. 
Proposed method-dependent SYO ECV for A. fumigatus and posaconazole is 0.06 µg/ml, as reported 
elsewhere (23). C. krusei is intrinsically resistant to fluconazole regardless of the MIC. 
 
cECV as estimated using the second derivative method (30).  
 
C. albicans 
 
8,747 
 
29/30 
 
0.008->16 
 
0.008 
 
0.01c 
 
 
C. dubliniensis 215 7/9 0.008-2 0.008 0.01c  
C. glabrata  3,255 24/30 0.008->16 0.25 2  
C. guilliermondii 157 11/12 0.008-≥16 0.06 0.5 
 
C. krusei 676 14/16 0.008-≥16 0.25 1  
C. lusitaniae 248 11/12        0.008-1         0.008 
 
0.03c 
 
C. parapsilosis   
C. parapsilosis SS 
2670 
718 
26/30 
4/5 
0.008-2 
0.008-2 
0.008 
0.008 
0.01c 
0.03c 
 
C. tropicalis 1,637 19/28 0.008->16 0.06 0.5  
A. fumigatus  
 
903 
 
8/8 
 
0.008->16 
 
0.25 
 
1 
 
 
A. flavus  389 6/7 0.008->16 0.25 1  
A. terreus 302 5/6 0.008-2 0.25 1  
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Table 4. Method-dependent Etest ECOFFinder ECVs of four triazoles for species of Candida and 
Aspergillusa 
 
aIncluding the complexes of C. parapsilosis, C. glabrata and Aspergillus spp.; C. krusei (P. kudriazveii). Variability or 
insufficient data precluded the proposal of ECVs for some species of both Candida and Aspergillus.  
bTotal number of laboratories included in the ECV definition pool/total number of laboratories that submitted data 
(including data from one published study) (20).  
cECVs for 97.5% of the statistically modelled population by ECOFFinder calculations and based on MICs by the 
commercial agar diffusion Etest method (15,29).  Proposed method-dependent Etest ECV for A. fumigatus and 
posaconazole was 0.25 µg/ml, as reported elsewhere (23). 
 
Agent and species 
 
No. 
isolates 
 
No. labs 
used/totalb 
 
MIC (µg/ml) 
ECVs (µg/ml)c  
 
Range Mode  
 
Fluconazole       
C. glabrata  356 7/10 0.12->128 8 64  
C. parapsilosis  639 9/9 0.03->128 0.5 4 
 
C. tropicalis 368 9/10 0.03->128 1 4 
 
 
Itraconazole 
      
C. albicans 975 8/9 <0.004->16 0.06 0.25 
 
C. krusei 101 3/3 0.03->16 0.5 2 
 
C. tropicalis 165 5/8 <0.004-8 0.03 0.5 
 
A. fumigatus 1,112 
 
10/10 
 
0.008->16 
 
0.5 
 
2 
 
 
A. flavus SC 250 7/8 0.01-2 0.25 1 
 
A. nidulans  130 4/4 0.01-8 0.12 1  
A. niger 176   4/5 0.03->16 1 4 
 
 
Posaconazolec 
    
 
 
C. albicans 305 4/6 <0.004-1 0.03 0.12  
C. parapsilosis  162 4/5 <0.004->16 0.01 0.12  
C. tropicalis 101 4/5 0.008-8 0.03 0.12  
A. flavus 204 7/7 0.01-1 0.25 0.5  
A. niger 168 4/5 0.03-1 0.25 0.5  
A. terreus 194 5/5 0.03-4 0.12 0.25  
       
Voriconazole       
C. albicans 2,159 8/11 <0.004->16 0.008 0.03  
C. glabrata  551 8/9 0.008->16 0.25 2  
C. krusei 130 6/6 0.01-8 0.5 2  
C. parapsilosis   506 7/9 <0.004->16 0.06 0.25 
 
C. tropicalis 260 6/10 <0.004-8 0.12 0.5  
A. fumigatus 1,409 7/7 <0.004->16 0.12 0.5 
 
 
A. flavus 257 7/7 0.01->16 0.25 0.5 
 
A. niger  173 4/5 0.01->16 0.25 1  
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Table 5. Triazole SYO and Etest MICs for selected confirmed C. albicans ERG11 and A. fumigatus 
sensu stricto cyp51 mutantsa 
 
Species/agent Mutation/ 
Method 
No. of mutants with MIC (µg/ml) of:b Total mutants 
<ECVb 
Fluconazole SYO 0.12 0.25 0.5 1 2 4 >8  
C. albicans E266D 
E266D/V4881 
  1 2 
1 
  7 
7 
3 
1 
 V112I/G450R  
 
 1    3 1 
 K128T  
 
2    1 2 
 D116E/K128T/
V159I 
3 1      4 
 
 
       
11/59  
Itraconazole SYO <0.06 0.12 0.25 0.5 1 2 >8  
C. albicans E266D 
E266D/V4881 
 1 
1 
 
   7 
7 
2 
1 
 V112I/G450R 1   4   1 1 
 D116E/K128T/ 
V159I 
3      1 3 
 
        
6/59 
Posaconazole SYO <0.06 0.12 0.25 0.5 1 2 >8  
 C. albicans V112I/G450R 
D116E/K128T/ 
V159I 
 
1 
3 
 
 
  2 1   
1 
1 
3 
4/59 
Voriconazole SYO <0.01 0.03 0.06 0.12 0.25 0.5 >1  
C. albicans E266D 
E266D/V4881 
1 
1 
1  2   6 
7 
1 
1 
 K128T 
D116E/K128T 
1 
4 
1 
 
   1 
4 
1 
4 
    
 
    7/59 
Itraconazole Etest <0.06 0.12 0.25 0.5 1 2 >8  
A. fumigatus G448S 
M220K 
   1 
 
  
1 
4 1 
1 
 I301T 1      1 1 
         3/81 
Voriconazole Etest <0.06 0.12 0.2 0.5 1 2 >4  
A. fumigatus TR34  1  2 14 11 10 3 
 G54E/R/W 2 2 5 3    12 
 M220I/K//R/T/
V 
 3 1 4  2 1 8 
 
G138C   1     1 
 I301T 1       1 
 
        25/75 
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(Cont. Table 5)          
Voriconazole SYO <0.06 0.12 0.25 0.5 1 2 >4  
A. fumigatus TR34   
 
 1   1 
 
G54E/R/W  2 1 2    5 
 M220I/K/T/V   2 3    5 
 G138C 
  
1     1 
 I301T  1 
 
    1 
    
     
13/39 
aListed are SYO and Etest MICs for C. albicans and A. fumigatus mutants that were either below and/or 
above (shaded and non-shaded, respectively) each correspondent ECV among the total data points for the 59 
C. albicans and 75 or 81 or 39 A. fumigatus mutants. Data submitted from multiple participant laboratorios (4 
to 8) and a single published study (20). 
 
bThe proposed SYO ECVs were: C. albicans versus fluconazole (1 µg/ml), itraconazole (0.12 µg/ml), 
posaconazole (0.06 µg/ml) and voriconazole (0.01 µg/ml); and for A. fumigatus and voriconazole (1 µg/ml). 
Etest ECVs were: A. fumigatus versus itraconazole (2 µg/ml) and voriconazole (0.5 µg/ml). 
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Table 6. Method-dependent ECVs of four triazoles for species of Candida, Saccharomyces, and Aspergillus by three susceptibility testing 
methodsa 
 
aSYO/Etest proposed ECVs in the present study, based on MICs determined by both commercial, respectively, and CLSI broth microdilution (M27 and M38) methods 
(11,12,14,15). C. guilliermondii (M. guilliermondii), C. krusei (P. kudriavzevii) and C. lusitaniae (Clavispora lusitaniae).  
bPosaconazole ECVs for A. fumigatus as reported elsewhere (23,26); the SYO ECV for C. orthopsilosis was 4 µg/ml. 
AM: aberrant modes, modal variability; ID, insufficient number of laboratories/isolates entering the ECV definition pool. 
 NA:  not available or applicable. 
 
Species 
Agent/ Method-dependent ECVs (µg/ml) 
FLU ITR POS VOR 
 SYO Etest CLSI SYO Etest CLSI SYO Etest CLSI SYO Etest CLSI 
C. albicans 1 AM 0.5 0.12 0.25 NA 0.06 0.12 0.06 0.01 0.03 0.03 
C. dubliniensis 1 ID 0.5 0.25 ID NA 0.12 ID 0.25 0.01 ID 0.03 
C. glabrata 
C. guilliermondii 
64 
16 
64 
ID 
8 
8 
2 
1 
8 
ID 
4 
NA 
4 
1 
ID 
ID 
1 
0.5 
2 
0.5 
2 
ID 
0.25 
0.12 
C. krusei 128 ID 32 1 2 1 1 ID 0.5 1 2 0.5 
C. lusitaniae 4 ID 1 0.5 ID 0.5 0.12 ID 0.06 0.03 ID 0.06 
C. parapsilosis SC  
C. parapsilosis SS 
C. tropicalis 
2 
2 
4 
4 
NA 
4 
1 
NA 
1 
0.25 
0.5 
0.5 
AM 
NA 
0.5 
NA 
NA 
0.5 
0.12 
0.25 
1 
0.12 
NA 
0.12 
0.25 
NA 
0.12 
0.01 
0.03 
0.5 
0.25 
NA 
0.5 
0.03 
NA 
0.12 
S. cerevisiae 16 ID NA ID ID NA ID ID NA ID ID NA 
A. fumigatus NA NA NA AM 2 1 0.06b 0.25b 0.25b 1 0.5 1 
A. flavus NA NA NA AM 1 1 NA 0.5 0.5 1 0.5 2 
A. niger NA NA NA 1 4 4 NA 0.5 2 ID 1 2 
A. terreus NA NA NA AM AM 2 NA 0.25 1 1 AM 2 
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